Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Gary A Ulaner

Showing results (141-150 of 152) with videos related to

Pageof 16
Sort By:
Journal of the American College of Radiology : JACR|June 1, 2024
ACR Appropriateness Criteria® Female Breast Cancer Screening: 2023 Update, Bethany L Niell, Maxine S Jochelson, et al.
Journal of the American College of Radiology : JACR|November 5, 2025
ACR Appropriateness Criteria® Female Breast Cancer Screening: 2025 Update, Eren D Yeh, Ann Brown, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|July 11, 2018
Ado-Trastuzumab Emtansine for Patients With HER2-Mutant Lung Cancers: Results From a Phase II Basket TrialBob T Li, Ronglai Shen, Darren Buonocore, et al.
British Journal of Haematology|April 13, 2024
Mixed histiocytic neoplasms: A multicentre series revealing diverse somatic mutations and responses to targeted therapyJoshua S Friedman, Benjamin H Durham, Anne S Reiner, et al.
Journal for Immunotherapy of Cancer|March 27, 2026
CD8 PET imaging with [<sup>89</sup>Zr]Zr-berdoxam-crefmirlimab in patients with solid tumors: the Phase II iCorrelate studyMichael A Postow, Peter D Zang, Sumanta K Pal, et al.
Nature Medicine|November 27, 2019
Activating mutations in CSF1R and additional receptor tyrosine kinases in histiocytic neoplasmsBenjamin H Durham, Estibaliz Lopez Rodrigo, Jennifer Picarsic, et al.
Nature Communications|July 19, 2020
Accelerated single cell seeding in relapsed multiple myelomaHeather J Landau, Venkata Yellapantula, Benjamin T Diamond, et al.
Cancer Cell|October 24, 2025
RAF-independent MEK mutations drive refractory histiocytic neoplasms but respond to ERK inhibitionEli L Diamond, Jean-Francois Emile, Takeshi Fujino, et al.
Nature|February 14, 2019
Author Correction: HER kinase inhibition in patients with HER2- and HER3-mutant cancersDavid M Hyman, Sarina A Piha-Paul, Helen Won, et al.
Nature|February 9, 2018
HER kinase inhibition in patients with HER2- and HER3-mutant cancersDavid M Hyman, Sarina A Piha-Paul, Helen Won, et al.
Pageof 16

Showing results (141-150 of 152) with videos related to

Sort By:
Pageof 16
Journal of the American College of Radiology : JACR|June 1, 2024
ACR Appropriateness Criteria® Female Breast Cancer Screening: 2023 Update, Bethany L Niell, Maxine S Jochelson, et al.
Journal of the American College of Radiology : JACR|November 5, 2025
ACR Appropriateness Criteria® Female Breast Cancer Screening: 2025 Update, Eren D Yeh, Ann Brown, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|July 11, 2018
Ado-Trastuzumab Emtansine for Patients With HER2-Mutant Lung Cancers: Results From a Phase II Basket TrialBob T Li, Ronglai Shen, Darren Buonocore, et al.
British Journal of Haematology|April 13, 2024
Mixed histiocytic neoplasms: A multicentre series revealing diverse somatic mutations and responses to targeted therapyJoshua S Friedman, Benjamin H Durham, Anne S Reiner, et al.
Journal for Immunotherapy of Cancer|March 27, 2026
CD8 PET imaging with [<sup>89</sup>Zr]Zr-berdoxam-crefmirlimab in patients with solid tumors: the Phase II iCorrelate studyMichael A Postow, Peter D Zang, Sumanta K Pal, et al.
Nature Medicine|November 27, 2019
Activating mutations in CSF1R and additional receptor tyrosine kinases in histiocytic neoplasmsBenjamin H Durham, Estibaliz Lopez Rodrigo, Jennifer Picarsic, et al.
Nature Communications|July 19, 2020
Accelerated single cell seeding in relapsed multiple myelomaHeather J Landau, Venkata Yellapantula, Benjamin T Diamond, et al.
Cancer Cell|October 24, 2025
RAF-independent MEK mutations drive refractory histiocytic neoplasms but respond to ERK inhibitionEli L Diamond, Jean-Francois Emile, Takeshi Fujino, et al.
Nature|February 14, 2019
Author Correction: HER kinase inhibition in patients with HER2- and HER3-mutant cancersDavid M Hyman, Sarina A Piha-Paul, Helen Won, et al.
Nature|February 9, 2018
HER kinase inhibition in patients with HER2- and HER3-mutant cancersDavid M Hyman, Sarina A Piha-Paul, Helen Won, et al.
Pageof 16